Products with Neuroprotection bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN5062 | 3,8-Di-O-methylellagic acid |
| 3,3'-Di-O-methylellagic acid reveals moderate antibacterial activity, it also shows strong DPPH radical scavenging activities with SC50 of 123.3 ug/mL. It has a lower capacity of stimulating murine peritoneal macrophages to release nitric oxide and tumoural-alpha necrose factor. 3,3'-Di-O-methylellagic acid may be a useful as pharmacological agent for the treatment of neurodegenerative diseases. | |
| BCN5065 | Falcarindiol |
| Falcarindiol has antimutagenic, neuroprotective, antifungal, anti-bacterial, and anticancer activities, it could be potentially used in food manufactures and cosmetology as preservative agents and biopesticides, or in medicine as new antibiotics. Falcarindiol has protective effects against CCl(4) toxicity, in part, the effects might be explained by anti-lipid peroxidation activity associated with the induction of the GSTs including GSTA4. | |
| BCN5094 | Catalpol |
| Catalpol is a kind of enzyme inhibitors, it has been shown to have antioxidation, anti-inflammation, anti-apoptosis and other neuroprotective properties and plays a role in neuroprotection against hypoxic/ischemic injury, AD and PD in both in vivo and in vitro models.Catalpol regulates cholinergic nerve system function through effect on choline acetyl-transferase not M receptor affinity, it has a wide spectrum of targets including Bcl-2 , PI3K, Akt-eNOS, caspase. | |
| BCN5103 | Bryonolic acid |
| 1. Bryonolic acid has anti-allergic activity. 2. Bryonolic acid exhibits cytotoxic activity to various tumor cells in vitro, independent of cell type. 3. Bryonolic acid can induce a marked increase in the expression of a phase 2 response enzyme, heme oxygenase 1 (HO-1), in a dose-dependent manner. 4. Bryonolic acid can protect PC12 cells against NMDA-induced apoptosis by inhibiting Ca2+ influx and regulating gene expression in the Ca2+-CaMKII-CREB signal pathway, supports that it may be a promising neuroprotective agent for the treatment of cerebral ischemia disease. 5. Bryonolic acid has anti-inflammatory and antioxidant activities, it can reduce the inflammatory mediator NO by suppressing the expression of the inflammatory enzyme inducible nitric oxide synthase (iNOS) in LPS-activated RAW 264.7 macrophage cells. | |
| BCN5104 | Geniposide |
| Geniposide exhibits anti-diabetic, antidepressant-like, antioxidative, anti-apoptotic, antiproliferative and neuroprotective activities. Geniposide is an agonist for GLP-1 receptor, it regulates expression of anti-oxidative proteins including HO-1 and Bcl-2 by activating the transcriptor of p90RSK via MAPK signaling pathway in PC12 cells. Geniposide may suppress TGF-β1-induced EMT in hepatic fibrosis by inhibiting the TGFβ/Smad and ERK-mitogen-activated protein kinase (MAPK) signaling pathways. | |
